Kura Oncology, Inc. KURA 深 滬
等待開盤 06-25 09:30:00 美东时间
10.62
+0.240
+2.31%
華盛通- 最 高11.00
- 今 開10.58
- 成交量 130.40万股
- 最 低 10.565
- 昨 收 10.38
- 總市值 9.43亿
- 52周最高 12.49
- 市盈率 靜 --
- 換手率 1.47%
- 52周最低 5.45
- 委 比 87.83%
- 總股本 8877.44万
- 歷史最高 43.00
- 量 比 0.93
- 振 幅 4.19%
- 歷史最低 2.50
- 每 手 1
- 風險率 1.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Kura Oncology And Kyowa Kirin Announce Long-Term Results From The Phase 1/2 KOMET-007 Single-Arm Trial Evaluating Ziftomenib In Combination With Intensive Chemotherapy
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced encouraging long-term results from the Phase 1/2 KOMET-007 single-arm trial (NCT05735184) evaluating ziftomenib in combination with intensive chemotherapy, 7+3, in newly diagnosed NPM1-m or KMT2A-r...
06-11 20:09
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology granted inducement awards of 53,000 nonstatutory stock options to four new employees under its 2023 Inducement Option Plan. The options, exercisable at $9.04 per share, vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment. The awards align with Nasdaq Listing Rule 5635(c)(4).
06-05 11:30
Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –– Central MRD negativity in 75% of CRc responders with no prior venetoclax
06-02 20:44
Kura Oncology Announces First-In-Human Data From The FIT-001 Clinical Trial Of Darlifarnib In Combination With Adagrasib In Heavily Pretreated Patients With KRAS G12C-Mutated Advanced Solid Tumors
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –– ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients –– Results
05-26 18:12
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology reported promising results from the FIT-001 trial combining darlifarnib and adagrasib in KRAS G12C-mutated solid tumors. The combination showed tumor shrinkage in 77% of patients, with ORRs of 67% in PDAC, 50% in NSCLC, and 29% in CRC. Darlifarnib demonstrated consistent activity across tumor types and manageable safety, reinforcing its potential as a precision combination agent. Results will be presented at the 2026 ASCO meeting, w...
05-26 10:02
Kura Oncology Q1 EPS $(0.83) Beats $(0.94) Estimate, Sales $18.265M Miss $18.513M Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.94) by 11.7 percent. This is a 25.76 percent decrease over losses of $(0.66) per share from the
05-13 04:03
Kura Oncology Announces Acceptance Of Its Updated Results From Phase 1 KOMET-007 Clinical Study Of Ziftomenib In Combination With Cytarabine Plus Daunorubicin For Presentation At 2026 European Hematology Association Congress
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that updated results from the frontline arm of the Phase 1 KOMET-007 (NCT05735184) clinical trial evaluating
05-12 21:59
Kura updates ziftomenib-plus-7+3 trial data in frontline AML at EHA 2026
Kura updates ziftomenib-plus-7+3 trial data in frontline AML at EHA 2026 Kura Oncology outlined updated early-stage trial results for ziftomenib combined with standard intensive induction chemotherapy in newly diagnosed genetically defined acute myeloid leukemia, with data scheduled for oral present
05-12 21:46
Kura Oncology Reports First Quarter 2026 Financial Results
Kura Oncology reported first-quarter 2026 financial results, with $5.8 million in net product revenue for KOMZIFTI™ (ziftomenib) in its first full quarter of commercialization. The company achieved strong early momentum with 85 new patient starts, 157 total prescriptions, and over 93% payer coverage. Clinical advancements include ongoing trials across AML treatment settings, with multiple data readouts expected in 2026. Kura also highlighted its ...
05-12 20:02
